CRISPR Therapeutics Valuation Multiples

CRISPR Therapeutics Overview

About CRISPR Therapeutics

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Founded

2013

HQ

Employees

393

Website

crisprtx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $13M

EBITDA: ($576M)

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

CRISPR Therapeutics Financials

CRISPR Therapeutics reported last 12-month revenue of $13M and negative EBITDA of ($576M).

In the same LTM period, CRISPR Therapeutics generated $11M in gross profit, ($576M) in EBITDA losses, and had net loss of ($551M).

CRISPR Therapeutics P&L

In the most recent fiscal year, CRISPR Therapeutics reported revenue of $4M and EBITDA of ($615M).

CRISPR Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics has current market cap of $6B, and enterprise value of $4B.

CRISPR Therapeutics' stock price is $60.77.

CRISPR Therapeutics Valuation Multiples

CRISPR Therapeutics trades at 310.5x EV/Revenue multiple, and (7.1x) EV/EBITDA.

CRISPR Therapeutics Financial Valuation Multiples

As of March 18, 2026, CRISPR Therapeutics has market cap of $6B and EV of $4B.

Equity research analysts estimate CRISPR Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CRISPR Therapeutics has a P/E ratio of (10.6x).

CRISPR Therapeutics Margins & Growth Rates

CRISPR Therapeutics' revenue in the last 12 month grew by 430%.

CRISPR Therapeutics' revenue per employee in the last FY averaged $0.0M.

CRISPR Therapeutics' rule of 40 is (3971%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CRISPR Therapeutics' rule of X is (3326%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

CRISPR Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

CRISPR Therapeutics M&A Activity

CRISPR Therapeutics acquired XXX companies to date.

Last acquisition by CRISPR Therapeutics was on XXXXXXXX, XXXXX. CRISPR Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

CRISPR Therapeutics Investment Activity

CRISPR Therapeutics invested in XXX companies to date.

CRISPR Therapeutics made its latest investment on XXXXXXXX, XXXXX. CRISPR Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).